TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12551868
Drug: abciximab (48-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (48-hour infusion) in patients with negative troponin
Study: 12551868
Drug: abciximab (48-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (48-hour infusion) in patients with elevated C-reactive protein
Study: 10383508
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. and clarithromycin 500 mg t.d.s. for 14 days (OC14 group)
Study: 10383508
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d., clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. for 7 days (OCA7 group)
Study: 6831755
Drug: Metronidazole alone
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole alone or in combination with systemic antibiotics
Study: 30730476
Drug: Group MP
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group MP (300 mg pregabalin orally + IV magnesium sulfate 50 mg/kg)
Study: 30730476
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P (300 mg pregabalin orally + placebo IV infusion)
Study: 30730476
Drug: Group M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M (placebo capsule + IV magnesium sulfate 50 mg/kg)
Study: 30730476
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (placebo capsule + placebo IV infusion)
Study: 27321385
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg vildagliptin twice daily
Study: 27321385
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sitagliptin once daily
Study: 21054461
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg) with Eurycoma longifolia (200 mg)
Study: 21054461
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg) with placebo (Lactose)
Study: 9580647
Drug: Intranasal live
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (one dose)
Study: 9580647
Drug: Intranasal live
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (two doses)
Study: 9580647
Drug: Intranasal live
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal live attenuated, cold-adapted, trivalent influenzavirus vaccine (both regimens)
Study: 9580647
Drug: Intranasal live
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal live attenuated, cold-adapted influenzavirus vaccine
Study: 8072261
Drug: Dipyridamole and
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole and aspirin combination
Study: 8072261
Drug: Dipyridamole and
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole and aspirin
Study: 2647156
Drug: Intravenous amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amphetamine infusion (0.3 mg/kg)
Study: 30670760
Drug: Negative control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control, no treatment
Study: 23095869
Drug: TUTI-16 vaccine
Normalized name: L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 6 vaccine Prefilled Syringe [Gardasil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TUTI-16 vaccine
Study: 19235040
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isoflavones daily
Study: 19235040
Drug: 140 mg
Normalized name: caffeine 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg isoflavones daily
Study: 17702736
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aliskiren 150 mg and Valsartan 160 mg
Study: 9813387
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg, clarithromycin 250 mg and metronidazole 400 mg (OCM) given three times daily for 10 days
Study: 9813387
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg and amoxicillin 1 g (OA) given twice daily for 14 days
Study: 8569256
Drug: Water injection
Normalized name: electroly,inj/dextrose-water INJECTION AMPUL (ML)
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water injection at Qimen, Riyue, and Juque points
Study: 26314625
Drug: NBP607 (cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBP607 (cell culture-derived inactivated trivalent influenza vaccine)
Study: 26314625
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (AgrippalS1, egg-based subunit vaccine)
Study: 22746145
Drug: Psychosocial circumstances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial circumstances at treatment start
Study: 19535679
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (500-ml intragastric infusion)
Study: 19535679
Drug: Fructose solution
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose solution (500-ml intragastric infusion)
Study: 19535679
Drug: Aspartame solution
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame solution (500-ml intragastric infusion)
Study: 19535679
Drug: Saccharin solution
Normalized name: Saccharin
DrugBank: Saccharin (DB12418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharin solution (500-ml intragastric infusion)
Study: 19535679
Drug: Sweeter glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweeter glucose + saccharin solution (500-ml intragastric infusion)
Study: 19535679
Drug: Quinine solution
Normalized name: quinine Injectable Solution
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine solution (500-ml intragastric infusion)
Study: 19535679
Drug: Naringin solution
Normalized name: Naringin
DrugBank: Naringin (DB16859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naringin solution (500-ml intragastric infusion)
Study: 17525598
Drug: Continuous intrawound
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrawound infusion with 300 mg diclofenac
Study: 17525598
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion with systemic diclofenac (75 mg IV every 12 h for 48 h)
Study: 17525598
Drug: Local ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local ropivacaine infusion with systemic diclofenac (75 mg IV every 12 h for 48 h)
Study: 11588535
Drug: Manidipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine (10-20 mg, once daily)
Study: 606789
Drug: Killed split
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed split or whole bivalent influenza vaccine (A/New Jersey/76-A/Victoria/75)
Study: 27535276
Drug: Leech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leech therapy (5 leeches applied to the affected knee, once every week for 3 weeks)
Study: 24728028
Drug: TENS therapy
Normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS therapy
Study: 25987441
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin supplementation (AVS) [vitamins C (500 mg), E (400 IU), beta‐carotene (15,000 IU), zinc (7.5 mg), selenium (50 mg), copper (1 mg), and manganese (2.5 mg)] for 4 weeks
Study: 22776518
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral intake within 5 days postoperatively
Study: 22776518
Drug: Late oral
Normalized name: Adalate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late oral intake starting from postoperative day 6
Study: 9441769
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral intake
Study: 16940981
Drug: Pemetrexed (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (300 to 1,200 mg m(‐2) with FA/VB(12))
Study: 26164495
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole, twice daily for 4 weeks
Study: 26164495
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole, twice daily for an additional 4 weeks
Study: 24131496
Drug: IMPACT Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPACT Therapy (HPI)
Study: 21960073
Drug: TIVA (propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA (propofol at 100‐150 mg/kg/min and remifentanil at 2.0 mg/kg/min)
Study: 17880950
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose step‐up regimen
Study: 17880950
Drug: Sequential step‐up/step‐down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential step‐up/step‐down regimen
Study: 16797240
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg/day and Aspirin 100 mg/day
Study: 10688831
Drug: Lepirudin (Refludan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lepirudin (Refludan, bolus: 0.1 mg/kg, infusion: 0.1 mg/kg/h for 5 hours)
Study: 9354207
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg o.m.
Study: 16355622
Drug: Fengbei Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fengbei Huayu recipe (FHR) twice a day for 8 weeks
Study: 16355622
Drug: Conventional hypoglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hypoglycemic agents and hypotensor
Study: 14596580
Drug: Individualized behavioral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized behavioral treatments
Study: 11279324
Drug: Captopril (25-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25-75 mg daily)
Study: 11279324
Drug: Fosinopril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (10-20 mg daily)
Study: 6337032
Drug: Clonidine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (average 0.24 mg/day)
Study: 6337032
Drug: Propranolol (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (average 105 mg/day)
Study: 23094900
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: 41 ml of levobupivacaine 0.5 % + 1 ml magnesium sulfate (150 mg)
Study: 23094900
Drug: Group IV:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IV: 41 ml of levobupivacaine 0.25 % + 1 ml magnesium sulfate (150 mg)
Study: 23094900
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: 41 ml of levobupivacaine 0.5 % + 1 ml NaCl 0.9 %
Study: 23094900
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: 41 ml of levobupivacaine 0.25 % + 1 ml NaCl 0.9 %
Study: 16137437
Drug: Weekly epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly epirubicin
Study: 10915232
Drug: Diltiazem retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem retard (100-200mg once daily)
Study: 8864318
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (200 mg to 1600 mg)
Study: 8864318
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (up to 1600 mg)
Study: 6432325
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of ketoprofen
Study: 24661817
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin
Study: 9822949
Drug: no-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no-treatment control group
Study: 7860418
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of a long-acting GnRH agonist microcapsule formulation (Lupron Depot) on days 1 and 30; 4 mg/day testosterone replacement
Study: 7860418
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of a long-acting GnRH agonist microcapsule formulation (Lupron Depot) on days 1 and 30; 8 mg/day testosterone replacement
Study: 7860418
Drug: Treatment period
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period (9 weeks)
Study: 2468962
Drug: PK 11195
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 11195 (200 mg orally)
Study: 2468962
Drug: Nicardipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (20 mg orally)
Study: 2468962
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PK 11195 and Nicardipine
Study: 25262253
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg/d)
Study: 913294
Drug: Hydrochlorothiazide-triamterene (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide-triamterene (25 and 50 mg/d)
Study: 6782605
Drug: IV physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV physostigmine administration
Study: 27336726
Drug: Ribociclib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (400 mg/day) plus letrozole (2.5 mg/day)
Study: 27336726
Drug: Ribociclib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (600 mg/day) plus letrozole (2.5 mg/day)
Study: 27336726
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/day) alone
Study: 25027304
Drug: Glycopyrronium MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium MDI at 14.4, 28.8, 57.6, and 115.2 μg
Study: 18577933
Drug: Berlition (contains
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berlition (contains a-lipoic acid) used in neuroprotective therapy for chronic brain ischemia
Study: 15844495
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 200 mcg twice daily, commencing 6 weeks after FESS
Study: 10482177
Drug: Intravenous cariporide
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cariporide 20 mg every 8 hours
Study: 10482177
Drug: Intravenous cariporide
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cariporide 80 mg every 8 hours
Study: 10482177
Drug: Intravenous cariporide
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cariporide 120 mg every 8 hours
Study: 10482177
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (cariporide and placebo)
Study: 29995455
Drug: Rifaximin‐α 550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin‐α 550 mg twice daily plus lactulose
Study: 27584836
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment alone (MTA group)
Study: 19395187
Drug: High-risk patients
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk patients with PRPH-PSA <=0.1 ng/ml
Study: 1785031
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (1.0 watt/cm2 at 1 MHz, for 10 min) twice weekly for 8 weeks
Study: 6101791
Drug: Human leucocyte
Normalized name: Human leucocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leucocyte interferon (12 x 10(6) reference units daily for the first week, then halved weekly for six weeks)
Study: 19014790
Drug: Contraceptive Patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive Patch (CP)
Study: 10522500
Drug: Topical ascorbic
Normalized name: ascorbic acid Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ascorbic acid (Cellex‐C high‐potency serum)
Study: 8746883
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg daily) + Calcium (1000 mg daily)
Study: 15700052
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg daily)
Study: 1838079
Drug: 17 beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐oestradiol 1.5 mg on days 1‐12 and 17 beta‐oestradiol 1.5 mg + desogestrel 150 micrograms on days 13‐24 (E2/DG)
Study: 1838079
Drug: oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oestradiol valerate 2 mg on days 1‐11 and oestradiol valerate 2 mg + medroxyprogesterone acetate 10 mg on days 12‐21 (E2V/MPA)
Study: 7193582
Drug: Phenylpropanolamine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine, 50 mg twice daily
Study: 20231319
Drug: Meta-cognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-cognitive therapy
Study: 26109630
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus irinotecan (oral S-1 40-60 mg/m² on days 1-14 and intravenous irinotecan 150 mg/m² on day 1 of a 21-day cycle)
Study: 26109630
Drug: irinotecan-alone (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan-alone (intravenous irinotecan 150 mg/m² on day 1 of a 14-day cycle)
Study: 23637556
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg + Hydrochlorothiazide 25 mg (T80/H25)
Study: 23637556
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg (T80)
Study: 16678551
Drug: Sibutramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (15 mg per day for 5 days)
Study: 15225889
Drug: Nicotine pretreatment
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine pretreatment via a transdermal patch (21 mg)
Study: 15225889
Drug: Ethanol administration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol administration (0.4 and 0.7 g/kg)
Study: 11295031
Drug: Standard dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysis dose
Study: 11295031
Drug: Higher dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dialysis dose
Study: 9207355
Drug: Sorivudine 40
Normalized name: Brivudine
DrugBank: Brivudine (DB03312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorivudine 40 mg once daily for 7 days
Study: 30113736
Drug: 2% triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% triple antibiotic paste (TAP)
Study: 30113736
Drug: 100% triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% triple antibiotic paste (TAP)
Study: 24458199
Drug: 300-mg sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg sustained-release tablet (SRT) of ONO-5334
Study: 24458199
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing of 300-mg sustained-release tablet (SRT) of ONO-5334
Study: 24458199
Drug: 300-mg immediate-release
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg immediate-release tablet (IRT) of ONO-5334
Study: 21435695
Drug: Diuretic initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Diuretic initiation
Study: 21435695
Drug: Diuretic discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic discontinuation
Study: 16814206
Drug: HPV testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV testing (> or = 1 pg/mL) with cytology triage
Study: 12763513
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral hormone replacement therapy (HRT)
Study: 8868968
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy with adolescents
Study: 1658652
Drug: Ganciclovir (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (5 mg/kg twice a day for one week, followed by 5 mg/kg per day)
Study: 6350071
Drug: Tioconazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tioconazole 1% cream applied twice daily for 14 days (pityriasis versicolor) or 28 days (dermatophyte and yeast infections)
Study: 6350071
Drug: Miconazole 2%
Normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole 2% cream applied twice daily for 14 days (pityriasis versicolor) or 28 days (dermatophyte and yeast infections)
Study: 24206639
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation treatment
Study: 27508536
Drug: Racecadotril (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril (1.5 mg/kg/dose, thrice a day for three days)
Study: 17634494
Drug: Ifosfamide 9
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide 9 g/m2 over 3 days continuous infusion
Study: 17634494
Drug: Ifosfamide 3
Normalized name: ifosfamide 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 3 g/m2 per day in 3 hours over 3 days
Study: 17634494
Drug: Standard doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doxorubicin 75 mg/m2 every 21 days
Study: 14691439
Drug: Tirofiban +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban + heparin
Study: 11720197
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone replacement therapy regimens (estrogen plus different progestogens)